{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218194","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-05-12T11:35:15+00:00","discovered_at":"2026-05-12T11:40:00.383958+00:00","generated_at":"2026-05-12T11:42:10.195093+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xilio Q1 net loss $9.5M; cash $150.3M; XTX501 IND planned mid-2026","bullets":["Cash and cash equivalents $150.3M at Mar 31, 2026 (vs $137.5M Dec 31, 2025); runway into early 2028.","Net loss $9.5M vs $13.3M YoY; collaboration revenue $12.6M (up from $2.9M); R&D $19.8M (up from $8.3M).","Achieved $6.0M development milestone under AbbVie collaboration (Q2 2026).","XTX501 IND submission planned mid-2026; Phase 1 start H2 2026; initial data H2 2027.","Appointed Cheryl R. Blanchard, Ph.D. to board of directors (April 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218194","json":"https://secwatch.observer/filing/0001193125-26-218194.json","markdown":"https://secwatch.observer/filing/0001193125-26-218194.md","text":"https://secwatch.observer/filing/0001193125-26-218194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/0001193125-26-218194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/xlo-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T11:42:10.195093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb03b6665bc48d453a84846eebe4bfe71a64fa94","claim":"Xilio Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $12.6 million.","evidence_excerpt":"Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, compared to $2.9 million for the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/0001193125-26-218194-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$12.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}